AstraZeneca PLC (AZN)
| Market Cap | 262.05B +0.8% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.75 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.97 |
| Forward PE | 15.63 |
| Dividend | $3.23 (1.92%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 1,896,879 |
| Open | 168.91 |
| Previous Close | 168.82 |
| Day's Range | 168.09 - 169.84 |
| 52-Week Range | 153.41 - 212.71 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 207.16 (+22.98%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $207.16, which is an increase of 22.98% from the latest price.
News
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says Ultomiris approved to reduce proteinuria
The company states: “Alexion, AstraZeneca (AZN) Rare Disease’s Ultomiris – ravulizumab – has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at...
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Results for Tezspire in Eosinophilic ...
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Results for Tezspire in Eosinophilic Esophagitis
AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
AstraZeneca (AZN) Reports Positive Phase 3 CROSSING Trial Results for Eosinophilic Esophagitis ...
AstraZeneca (AZN) Reports Positive Phase 3 CROSSING Trial Results for Eosinophilic Esophagitis Treatment
AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial
(RTTNews) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSSING trial showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults with eosinophi...
AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire
Full results from the “positive” Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the c...
AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements
Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary...
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
AstraZeneca (AZN) Partners with Oracle to Enhance Clinical Trials Using AI
AstraZeneca (AZN) Partners with Oracle to Enhance Clinical Trials Using AI
Oracle announces pact with AstraZeneca to advance AI-enabled healthcare
Oracle (ORCL) announced an agreement with AstraZeneca (AZN) to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, an...
AstraZeneca Partners with Oracle to Enhance Clinical Research Efficiency
AstraZeneca Partners with Oracle to Enhance Clinical Research Efficiency
AstraZeneca partners with Oracle for AI-driven clinical trials
AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drug...
Oracle stock's next big AI opportunity may have nothing to do with data centres
Oracle announced a healthcare artificial intelligence collaboration with AstraZeneca on Tuesday, expanding its ambitions beyond data centres as investors scrutinise the cost of its cloud infrastructur...
AstraZeneca Partners With Oracle to Refine Clinical Research With AI
AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
AstraZeneca, Oracle to launch their first global AI program in Abu Dhabi: CEO
AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first programme set for Abu Dhabi in partnership with M42. CNBC's Dan Murphy speaks...
AstraZeneca, Oracle Launch AI Collaboration To Optimise Clinical Trials
(RTTNews) - AstraZeneca PLC (AZN) and Oracle Health & Life Sciences (ORCL) announced on Tuesday the launch of a global Artificial Intelligence (AI) collaboration to improve clinical trial recruitment,...
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for ...
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI (durvalumab), TAGRISSO (osimertinib) and savolitinib
AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, O...
AstraZeneca announces new data across portfolio at ESMO 2026
AstraZeneca (AZN) announces new data across its portfolio and pipeline at the European Society for Medical Oncology, ESMO, Congress, 23-27 October 2026. Highlights include: CLARITY-Gastric01: Phase II...
Covid vaccine victim ‘not disabled enough’ for compensation
Marie-Claire Hoyle lost use of her hands and was numb from collarbone to thigh after receiving AstraZeneca jab during 2020 trial
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.
AstraZeneca (AZN) Partners with insitro in $1.5B AI-Driven Drug Discovery Collaboration
AstraZeneca (AZN) Partners with insitro in $1.5B AI-Driven Drug Discovery Collaboration